Mount Sinai study links early-life exposure to PFAS ("forever chemicals") with childhood intestinal inflammation
First-of-its-kind study finds prenatal and early-life exposure is associated with higher levels of a biomarker of intestinal inflammation measured years later in childhood
The Mount Sinai Hospital / Mount Sinai School of Medicine
NEW YORK, NY (July 16, 2026) — Researchers at the Icahn School of Medicine at Mount Sinai have found that exposure to per- and polyfluoroalkyl substances (PFAS), commonly known as "forever chemicals," during pregnancy and early life is associated with increased intestinal inflammation during childhood.
The findings, published July 10, 2026, in Clinical Gastroenterology and Hepatology, provide new evidence that environmental exposures during critical stages of development may influence long-term intestinal health and future inflammatory bowel disease (IBD) risk.
The study is the first to demonstrate that prenatal and early-life PFAS exposure is consistently associated with elevated levels of fecal calprotectin—a biomarker of intestinal inflammation commonly used to monitor IBD—across three birth cohorts in the United States and Mexico.
Researchers measured PFAS concentrations in maternal blood collected during pregnancy, umbilical cord blood, and newborn dried blood spots before following children for up to 11 years. Across all three birth cohorts, higher PFAS mixture levels were associated with higher fecal calprotectin levels later in childhood.
"While genetics play an important role in inflammatory bowel disease, they do not fully explain why the disease develops," said Manasi Agrawal, MD, MS, corresponding author of the study and Assistant Professor of Medicine (Gastroenterology), and Environmental Medicine and Public Health, at the Icahn School of Medicine. "Our findings suggest that prenatal and early-life PFAS exposure may contribute to intestinal inflammation during an important stage of development. Understanding these environmental influences may ultimately help us identify opportunities to reduce future disease risk before symptoms develop."
PFAS are a large family of synthetic chemicals used in products including nonstick cookware, food packaging, stain-resistant fabrics, and firefighting foams. Because these chemicals do not readily break down, they persist in the environment and can accumulate in the human body over time, leading to widespread human exposure.
Using advanced untargeted chemical analysis, the investigators detected PFAS across all early-life biological samples. They found that both legacy PFAS compounds and newer replacement PFAS were associated with intestinal inflammation, suggesting that a broad range of these chemicals may influence children's gut health.
"By studying PFAS as mixtures rather than individual chemicals, we were able to better reflect how people are exposed in everyday life," said Vishal Midya, PhD, MStat, first author of the study and Assistant Professor of Environmental Medicine and Public Health at the Icahn School of Medicine. "The consistency of our findings across multiple biological samples and three independent birth cohorts strengthens the evidence that early-life PFAS exposure may have lasting effects on intestinal health."
The researchers emphasize that elevated fecal calprotectin does not mean a child will develop IBD. Rather, it is a sensitive biomarker of intestinal inflammation that has been associated with an increased future risk of IBD. Because the study was observational, it cannot determine whether PFAS directly cause intestinal inflammation or IBD.
The research team plans to continue following participants to determine whether children with higher early-life PFAS exposure and intestinal inflammation are more likely to develop inflammatory bowel disease later in life. The findings also underscore the importance of public health strategies aimed at reducing PFAS exposure during pregnancy and early childhood.
The study included collaborators from the University of Iowa College of Public Health; the National Institute of Public Health in Cuernavaca, Mexico; Universidade de Lisboa, Portugal; Sheba Medical Center in Israel; and Aalborg University in Denmark.
The research was supported by the International Organization for the Study of Inflammatory Bowel Disease, the Crohn's & Colitis Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, and the National Institute of Diabetes and Digestive and Kidney Diseases.
###
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with approximately 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and leading schools of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care from conception through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes more than 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals,” “Best in State Hospitals,” “World’s Best Hospitals,” and “Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.
Journal
Clinical Gastroenterology and Hepatology
Subject of Research
People
Article Title
Per- and polyfluoroalkyl substances (PFAS) in early life is associated with childhood intestinal inflammation: analyses of three birth cohorts
Article Publication Date
10-Jul-2026
New solutions to the PFAS problem
HZDR research team develops methods for breaking down “forever chemicals”
Helmholtz-Zentrum Dresden-Rossendorf
image:
Plasma plus cavitation: Cold atmospheric plasma destroys toxic pollutants at the interface between gas bubbles and water.
view moreCredit: B. Schröder/HZDR
Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) have developed two new processes: Using hydrodynamic cavitation and cold atmospheric plasma combined with gas dispersion, they are looking to break down per- and polyfluoroalkyl substances (PFAS), industrial chemicals that are extremely resistant to chemical degradation. To support this effort, experts from the Helmholtz Centre for Environmental Research (UFZ) ran analyses that confirmed the degradation of PFAS and the release of fluoride. Once they reach market maturity, these processes could be used in industry, significantly reducing the release of PFAS into bodies of water (DOI: 10.1038/s41598-026-57490-6; DOI: 10.1016/j.ceja.2026.101046).
While some PFAS are suspected of altering genetic material and increasing the risk of cancer, the biological effects of many others remain unknown. This group of substances comprises more than 10,000 short- and long-chain industrial chemicals which owe their exceptional chemical resistance to their highly stable carbon-fluorine bonds. PFAS enter rivers and oceans via wastewater and are spreading worldwide. High concentrations of PFAS have also recently been detected in the Elbe River – a potential health hazard to plants, animals and humans alike.
In the context of the “National Water Strategy” to secure Germany’s drinking water supply and protect its bodies of water, researchers at HZDR are investigating how to reduce the burden on water bodies and specifically, how to systematically break down these “forever chemicals”. In a preliminary study, launched in 2022, a research team led by postdoctoral researcher Dr. Ysabel Huaccallo-Aguilar used a process known as hydrodynamic cavitation to degrade PFAS.
Cavitation breaks down stable bonds
“In hydrodynamic cavitation, we pass PFAS-enriched water through a constriction, generating small vapor bubbles,” explains Dr. Sebastian Reinecke, head of the Department of Water and Environmental Technologies at HZDR. Since long-chain PFAS are surface-active, they attach to the bubbles. “When the bubbles burst under the rising ambient pressure in the water downstream of the constriction, the PFAS that are attached to the bubbles are exposed to local temperature spikes of several thousand degrees Celsius,” Reinecke explains. At the same time, cavitation produces highly reactive hydroxyl radicals that react non-specifically with nearby substances. “Our hypothesis is that they attack the intermediate products, significantly boosting PFAS degradation.”
Ysabel Huaccallo-Aguilar and her colleagues were able to demonstrate that the process did break down PFAS in tap water while mineralizing organically bound fluorine. The longer the duration of the treatment, the higher the continuous increase in fluoride concentration in the solution. For their experiments, the researchers used perfluorooctane sulfonate (PFOS), a particularly persistent and well-studied compound from the PFAS group. By the end of the experiment, they were able to break down approximately 37 percent of the dissolved PFOS molecules at a stable degradation rate. “We are now conducting follow-up experiments to increase the degradation rate,” Reinecke explains. “Our goal is to improve the process to a degradation rate of more than 80 percent of the PFAS in the solution and mineralizing more than 50 percent of the fluorine that is bound in the chemicals – that means, breaking down the carbon-fluorine bonds that are typical of PFAS.”
Efficient PFAS degradation with highly reactive plasma species
In another series of experiments, environmental engineer Dr. Amit Kumar used cold atmospheric plasma in combination with gas dispersion to degrade PFAS. The advantage of this process is that it operates under ambient conditions and requires neither catalysts nor additional chemicals. In his PhD research, Kumar had already investigated ways of degrading micropollutants using the reactive chemical species that are generated in the plasma. He now applied his findings to this experiment. “We generated plasma at the water surface while simultaneously introducing gas into the PFAS-contaminated water,” says Sebastian Reinecke, explaining the experimental setup. “The PFAS attach to the surface of the gas bubbles. As they rise, the water is constantly circulated. This brings the PFAS to the surface, where they are broken down in the plasma.”
This method made it possible to almost completely degrade both long- and short-chain PFAS. About 35 percent of the fluorine atoms bound in these “forever chemicals” were released as fluoride salts. “While this method has significantly faster reaction kinetics than cavitation, it also consumes far more energy per volume unit,” Reinecke notes. “In addition, the process generates numerous transformation products that we have not yet been able to investigate in detail – for instance, gaseous compounds that form during the reaction.” The researchers are currently conducting further test series to find out whether the process produces any substances that may pose a health hazard, and if so, how to avoid it.
Synergies from combining plasma and cavitation
The researchers are currently working to scale up the process for larger volumes of contaminated water. Using multiple electrodes and a technical gas injector, they are gradually increasing the reaction volume from about 50 milliliters to five liters. The plan is to combine plasma technology with cavitation. “I believe we’ll achieve high degradation rates by combining the highly reactive species from the plasma with the effects of cavitation,” says Reinecke. If they succeed in merging the benefits of both methods into a single approach, they might create a whole new, efficient PFAS removal technology for contaminated water.
Publications:
Amit Kumar, Ysabel Huaccallo-Aguilar, Holger Kryk, Uwe Hampel, Sebastian Felix Reinecke: Enhanced degradation and defluorination of perfluorooctane sulfonate (PFOS) in tap water using gas-dispersed cold atmospheric plasma, in Scientific Reports, 2026 (DOI: 10.1038/s41598-026-57490-6).
Amit Kumar, Anett Georgi, Ysabel Huaccallo-Aguilar, Markus Meier, Holger Kryk, Sebastian Felix Reinecke, Uwe Hampel: Degradation and defluorination of perfluorooctane sulfonate (PFOS) forever chemical in water using hydrodynamic cavitation treatment, in Chemical Engineering Journal Advances, 2026 (DOI: 10.1016/j.ceja.2026.101046 ).
Funding:
This research was funded by the Helmholtz Association’s Impulse and Networking Fund via the Clean Water Technology Lab (CLEWATEC), a Helmholtz Innovation Lab, under reference number HIL-A02. The projects “HyKaPro SAB-EFRE” and “Plasma4PFAS SAB-EFRE” are co-financed by the European Union and tax revenue as approved by the Saxon Parliament in its state budget.
Further information:
Dr. Sebastian Reinecke | Head
Department of Water and Environmental Technologies
Institute of Fluid Dynamics at HZDR
Phone: +49 351 260 2320 | Email: s.reinecke@hzdr.de
Susann Riedel | Project Manager
Institute of Fluid Dynamics at HZDR
Phone: +49 351 260 3766 | Email: s.riedel@hzdr.de
Media Contact:
Simon Schmitt | Head
Communications and Media Relations at HZDR
Phone: +49 351 260-3400 | Email: s.schmitt@hzdr.de
The Helmholtz-Zentrum Dresden-Rossendorf (HZDR) performs – as an independent German research center – research in the fields of energy, health, and matter. We focus on answering the following questions:
- How can energy and resources be utilized in an efficient, safe, and sustainable way?
- How can malignant tumors be more precisely visualized, characterized, and more effectively treated?
- How do matter and materials behave under the influence of strong fields and in smallest dimensions?
To help answer these research questions, HZDR operates large-scale facilities, which are also used by visiting researchers: the Ion Beam Center, the Dresden High Magnetic Field Laboratory and the ELBE Center for High-Power Radiation Sources. HZDR is a member of the Helmholtz Association and has seven sites (Dresden, Freiberg, Görlitz, Grenoble, Leipzig, Rostock, Schenefeld near Hamburg) with almost 1,500 members of staff, of whom about 700 are scientists, including 200 Ph.D. candidates.
Journal
Scientific Reports
Method of Research
Experimental study
Subject of Research
Not applicable
Article Title
Enhanced degradation and defluorination of perfluorooctane sulfonate (PFOS) in tap water using gas-dispersed cold atmospheric plasma
No comments:
Post a Comment